ATNM_OUT_1 [2025-03-20 10:04:32 -0400] 2599 Bytes | 667 tokens | Cum: 667 tkns (8.34% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 10:04:31 AM on Thursday March 20, 2025 ET (UTC-0400), and I'm firing up the spotlight on Actinium Pharmaceuticals (ATNM), moving from 1.21 to 1.465. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for Actinium Pharmaceuticals:

C1 - Today 08:00AM - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
C2 - Mar-19-25 08:30AM - Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
C3 - Mar-19-25 08:30AM 08:11AM - Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
C4 - Mar-18-25 08:00AM - Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA and OPDIVO
C5 - Mar-17-25 08:50AM - Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
C6 - Mar-12-25 08:00AM - Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
C7 - Mar-11-25 08:30AM - Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
C8 - Nov-18-24 08:00AM - Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Actinium Pharmaceuticals (ATNM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ATNM_OUT_3 [2025-03-20 10:04:34 -0400] 968 Bytes | 244 tokens | Cum: 913 tkns (11.41% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy**
Date: Today 08:00AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-research-collaboration-with-memorial-sloan-kettering-to-support-further-clinical-expansion-of-actimab-as-backbone-therapy-strategy-302406589.html

NEW YORK,March 20, 2025/PRNewswire/ --Actinium Pharmaceuticals, Inc.(NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives. The first objective is to study Actimab-A in comb

-- More? (MOR) or Next section? (NEX)

ATNM_OUT_5 [2025-03-20 10:04:35 -0400] 1013 Bytes | 284 tokens | Cum: 1199 tkns (14.99% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T12:01:02Z - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support F...
A2 - 2025-03-19T12:44:04Z - Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of W...
A3 - 2025-03-18T17:27:00Z - Actinium Advances Actimab-A Trials In Combination With PD-1 Inhibitors For Solid Tumors...
A4 - 2025-03-18T17:32:15Z - Actinium Advances Actimab-A Trials In Combination With PD-1 Inhibitors For Solid Tumors...
A5 - 2025-03-18T13:46:09Z - Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with P...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ATNM_OUT_7 [2025-03-20 10:04:37 -0400] 968 Bytes | 260 tokens | Cum: 1461 tkns (18.26% of 8k)
==========================================================================

Showing A1 (chunk 1 of 10): A1:
**Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy**Date: 2025-03-20Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Announces+Research+Collaboration+with+Memorial+Sloan+Kettering+to+Support+Further+Clinical+Expansion+of+Actimab-As+Backbone+Therapy+Strategy/24526161.htmlNEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific o

-- More? (MOR) or Next section? (NEX)

ATNM_OUT_9 [2025-03-20 10:04:38 -0400] 968 Bytes | 206 tokens | Cum: 1669 tkns (20.86% of 8k)
==========================================================================

Showing A1 (chunk 2 of 10): bjectives. The first objective is to study Actimab-A in combination with targeted therapies including FLT3 and menin inhibitors to define transcriptional profiles in AML cells following treatment with these combinations. The second objective is to assess the activity of Actimab-A-based combinations on primary AML patient-derived ex vivo samples from patients with and without prior Venetoclax + hypomethylating agent (HMA) treatment. The collaboration will be done with members of MSKCC's leukemia and early drug development specialist teams.

Actimab-A has demonstrated a mutation agnostic profile with positive clinical results in high-risk relapsed and refractory (r/r) AML patients including those with a TP53 gene mutation, prior Venetoclax treatment and prior bone marrow transplant (BMT). Additionally, Actimab-A has demonstrated mechanistic synergy with improved antileukemic activity and /

-- More? (MOR) or Next section? (NEX)

ATNM_OUT_11 [2025-03-20 10:04:40 -0400] 1088 Bytes | 339 tokens | Cum: 2010 tkns (25.12% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-16T15:53:00Z - Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials
B2 - 2024-10-21T17:00:00Z - Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight
B3 - 2024-09-09T08:56:00Z - Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - Global Forecast 2024-2030
B4 - 2024-06-20T13:40:12Z - Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
B5 - 2024-06-04T13:40:10Z - Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
B6 - 2024-01-06T10:58:00Z - The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATNM_OUT_13 [2025-03-20 10:04:46 -0400] 864 Bytes | 216 tokens | Cum: 2228 tkns (27.85% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/16/2997669/28124/en/Targeted-Alpha-Therapy-Market-Drugs-Approval-Proprietary-Technologies-Clinical-Trials-20-Drugs-of-Targeted-Alpha-Therapy-In-Clinical-Trials.htmlThe article discusses the growing field of targeted alpha therapy, a novel approach in radiopharmaceuticals that utilizes alpha emitters to precisely target and eliminate diseased tissues. It highlights the approval of Xofigo, the first approved alpha-emitting radiopharmaceutical, and the surge of innovative preclinical and clinical candidates in development by various companies.

-- More? (MOR) or Next section? (NEX)

ATNM_OUT_15 [2025-03-20 10:04:48 -0400] 1126 Bytes | 284 tokens | Cum: 2631 tkns (32.89% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

S2 - 2024-08-05 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

S3 - 2024-08-05 8-K Item 7.01 Regulation FD Disclosure.

On August 5, 2024, Actinium Pharmaceuticals, Inc. (the Company) issued a press release announcing a regulatory update on the Companys planned Biologics License Application (BLA) filing for Iomab-B in patients with active relapsed or refractor...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

ATNM_OUT_17 [2025-03-20 10:04:50 -0400] 967 Bytes | 242 tokens | Cum: 2875 tkns (35.94% of 8k)
==========================================================================

Showing S3 (chunk 1 of 2): S3:
Item 7.01 Regulation FD Disclosure.

On August 5, 2024, Actinium Pharmaceuticals, Inc. (the Company) issued a press release announcing a regulatory update on the Companys planned Biologics License Application (BLA) filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (r/r AML). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated b

-- More? (MOR) or Next section? (NEX)

ATNM_OUT_19 [2025-03-20 10:05:09 -0400] 4361 Bytes | 1230 tokens | Cum: 4107 tkns (51.34% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Volume: 382,018 | SMA50: 17.85% | Market Cap: 44.30M | Option/Short: Yes / Yes | Sales past 5Y: -27.50% | Sales Surprise: - |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Avg Volume: 216.29K | SMA200: -49.69% | Shs Outstand: 31.20M | Short Float: 7.39% | Employees: 49 | EPS Surprise: -13.18% |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Rel Volume: 18.34 | Perf Week: 18.32% | Shs Float: 30.40M | Short Ratio: 10.39 | Debt/Eq: 0.04 | P/E: - |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| RSI (14): 66.03 | Perf Month: 21.36% | Inst Own: 28.73% | Short Interest: 2.25M | Sales Y/Y TTM: 80.00% | Earnings: Mar 14 |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| ATR (14): 0.08 | Perf Quarter: 11.80% | Insider Own: 2.54% | Beta: -0.09 | ROE: -100.05% | |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| SMA20: 21.31% | Index: RUT | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -103.95% | |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: Actinium Pharmaceuticals, Inc
Market Cap: 37747028.11
Shares Outstanding: 31195891
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 81000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -40915000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.465
Average Volume: 182283.04
30-Day High: 1.465
30-Day Low: 1.06

[Detailed Financials: Q3 2024]
- Total Assets: $82,114,000.0
- Total Liabilities: $43,906,000.0
- Total Equity: $38,208,000.0
- Current Assets: $79,520,000.0
- Current Liabilities: $7,755,000.0

[Income Statement: Q3 2024]
- Revenue: $0
- Net Income: $-11,568,000.0
- Operating Income: $-12,601,000.0
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-7,373,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $89,861,000.0
- Total Liabilities: $46,026,000.0
- Total Equity: $43,835,000.0
- Current Assets: $87,068,000.0
- Current Liabilities: $9,728,000.0

[Income Statement: Q2 2024]
- Revenue: $0
- Net Income: $-11,353,000.0
- Operating Income: $-12,418,000.0
- Earnings Per Share (EPS): -0.38

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $1,982,000.0
==== END OF FINANCIAL REPORT ====

ATNM_OUT_21 [2025-03-20 10:05:13 -0400] 561 Bytes | 131 tokens | Cum: 4542 tkns (56.77% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ATNM_IN_23 [2025-03-20 10:05:13 -0400] 126 Bytes | 29 tokens | Cum: 4636 tkns (57.95% of 8k)
==========================================================================

====================================
[2025-03-20 07:05:13] # Analysis Completed
Elapsed Time: 43.28 seconds